Psoriasis

These 28-week data on twice-daily ESK-001 highlight the drug’s safety and efficacy among patients with psoriasis.

Many patients struggle with therapeutic control, adverse effects, and costs of psoriasis treatments, prompting a renewed focus on alternative treatments like phototherapy.

Findings from a new study reveal significant racial differences in skin biopsy frequency for psoriasis diagnosis, indicating potential diagnostic challenges, particularly for Black patients.

A phase 2b clinical trial demonstrates the potential of zasocitinib in achieving biologic-level efficacy with minimal adverse effects.

Amgen announces new FDA-approved oral treatment option for children and adolescents with moderate to severe plaque psoriasis.

This new study confirms the noninferiority of extended dosing intervals for psoriasis control in super responders.

A recent study found psoriasis content deemed “unreliable” still obtained 850,000 likes.

Inflammatory markers can indicate treatment efficacy and predict super-responder status in patients with psoriasis treated with biologics, according to one study.

Biologic therapies may be less effective in patients with certain clinical characteristics, a meta-analysis found.

Patients with moderate-to-severe plaque psoriasis experienced early and sustained improvements through 108 weeks of treatment.

Patients with a later onset of psoriasis (PsO) may benefit from earlier screening for psoriatic arthritis (PsA), according to one study.

A bidirectional risk between psoriasis and asthma has been identified, according to one study.

Researchers have identified a link between psoriasis and the autoimmune diseases hypothyroidism and alopecia areata.

Researchers evaluated the impact of different treatment modalities in the prevention of psoriatic arthritis (PsA).

Patients with moderate to severe psoriasis may benefit from weekend cyclosporine treatment (WCT) as a maintenance therapy, according to one study.

Psychological well-being should be considered in the management of psoriasis, research indicates.

Botulinum toxin A (BoNT-A) exhibited promising results for nail psoriasis for up to 6 months with a single injection.

Efficacy results support long-term use of risankizumab in patients with active psoriatic arthritis across multiple patient and psoriatic disease characteristics.

Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.

Patients with moderate to severe psoriasis and a history of cancer have improved symptoms and a favorable safety profile with guselkumab treatment, according to a new study.

Roflumilast cream may be suitable for chronic treatment, including the face and intertriginous areas, according to one study.

Posters presented at the American Academy of Dermatology Annual Meeting identified significant undertreatment of psoriasis and significant gaps in biologic medication treatment.

Posters presented at the American Academy of Dermatology Annual Meeting demonstrated both short- and long-term efficacy and safety profiles of brodalumab in patients with moderate to severe psoriasis.

Patients experienced clinically meaningful improvements in health-related quality of life (HRQoL) factors after 6 months of guselkumab, according to one study.

Study findings show that scores on the Psoriasis Area and Severity Index and the Dermatology Quality of Life Index are correlated in patients with psoriasis across several continents, but factors affecting each of these scores are different across countries.

Researchers suggest an alternative method to align drug prices with clinical benefits for patients with psoriasis.

It is important to study the safety of targeted therapies in populations at increased risk of skin cancer, according to the researchers.

Risankizumab is an effective treatment option for patients with psoriatic arthritis (PsA), according to a recent meta-analysis.

Continuous improvement was observed across the different domains of minimal disease activity criteria with guselkumab.

People of color with scalp psoriasis experienced significant improvement in scalp itch and patient-reported health-related quality-of-life outcomes.